-+ 0.00%
-+ 0.00%
-+ 0.00%

NervGen says NVG-291 improves gait quality in Phase 1b/2a chronic tetraplegia study

PUBT·05/26/2026 11:15:24
Listen to the news
NervGen says NVG-291 improves gait quality in Phase 1b/2a chronic tetraplegia study
  • NervGen reported new independent, blinded gait-analysis results from its Phase 1b/2a CONNECT SCI trial of NVG-291 in chronic tetraplegia.
  • The analysis indicated patients on NVG-291 showed signs consistent with genuine neural recovery, not compensatory movement, versus placebo.
  • The findings support earlier reported improvements across multiple functional measures, reinforcing the program’s clinical signal in a chronic population.
  • The update underpins plans to start the Phase 3 RESTORE registrational study in mid-2026, with site activation underway.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260715PRIMZONEFULLFEED9726231) on May 26, 2026, and is solely responsible for the information contained therein.